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Abstract
Stereotactic body radiation therapy (SBRT) is an emerging locoregional treatment (LRT) modality used in the management
of patients with hepatocellular carcinoma (HCC). The decision to treat HCC with LRT is evaluated in a multidisciplinary
setting, and the specific LRT chosen depends on the treatment intent, such as bridge-to-transplant, down-staging to transplant, definitive/curative treatment, and/or palliation, as well as underlying patient clinical factors. Accurate assessment of
treatment response is necessary in order to guide clinical management in these patients. Patients who undergo LRT need
continuous imaging evaluation to assess treatment response and to evaluate for recurrence. Thus, an accurate understanding
of expected post-SBRT imaging findings is critical to avoid misinterpreting normal post-treatment changes as local progression or viable tumor. SBRT-treated HCC demonstrates unique imaging findings that differ from HCC treated with other
forms of LRT. In particular, SBRT-treated HCC can demonstrate persistent APHE and washout on short-term follow-up
imaging. This brief review summarizes current evidence for the use of SBRT for HCC, including patient population, SBRT
technique and procedure, tumor response assessment on contrast-enhanced cross-sectional imaging with expected findings,
and pitfalls in treatment response evaluation.
Keywords Hepatocellular carcinoma · Radiation therapy · Stereotactic body radiation therapy · Computed tomography ·
Magnetic resonance imaging

Introduction
Although the gold standard of care for hepatocellular carcinoma (HCC) is surgical resection, only 15–30% of patients
with HCC qualify for surgery. High tumor burden and
underlying liver dysfunction [1] often preclude patients
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from definitive resection [2]. For patients who are not surgical candidates and who have disease confined to the liver,
treatment with locoregional therapy (LRT) remains the most
effective treatment option. Patients with HCC should be
evaluated in a multidisciplinary setting, and LRT is chosen
depending on the intent of treatment, which could include
bridge-to-transplant, down-staging to transplant, definitive/
curative treatment, and/or palliation [3, 4]. Furthermore,
treatment choice varies depending on a host of clinical scenarios, including stage (extent of disease), performance status, and underlying liver function. While ablation or liver
transplantation are favored in patients with early-stage HCC,
locoregional therapies such as transarterial chemoembolization (TACE), transarterial radioembolization (TARE), and
stereotactic body radiation therapy (SBRT) have conventionally been reserved to treat more advanced unresectable
tumors [2].
Previous to recent technologic advances, radiation therapy (RT) was not typically used in the treatment of liver
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tumors due to the lack of daily image guidance, computed
tomography (CT)-based/magnetic resonance imaging
(MRI)-based radiation planning, and lack of understanding
of liver radiation tolerance, which resulted in high doses of
radiation to large volumes of adjacent uninvolved hepatic
parenchyma [5]. Historically, the resulting dose splash to
the liver using 3D conformal radiation caused moderate-tosevere toxicity manifested as compromised liver function
post radiotherapy. However, advances in the field of radiation oncology have allowed for refinement of radiation dose
delivery and target definition, resulting in the development
of stereotactic body radiation therapy (SBRT). SBRT is used
for the delivery of high dose radiation in a highly targeted
fashion, and with rapid dose drop off farther from the center
of the radiation zone [6]. This spares large portions of adjacent liver parenchyma, while simultaneously providing ablative doses to the tumor. SBRT is typically delivered in 3–5
fractions, with a relatively low risk of radiation-induced liver
disease (RILD). Numerous clinical trials have found SBRT
to be highly effective in providing local control for small
HCC tumors [7–9], although outcomes vary depending on
baseline liver function and data on long-term follow-up are
pending [10]. Although SBRT is not included in the current Barcelona Conference (BCLC) guidelines, it is included
in the most recent version of the National Comprehensive
Cancer Center guidelines for primary liver cancer as a treatment option for unresectable disease or medically inoperable
patients [11–13].

Patient selection and technique
SBRT can be used as definitive therapy, salvage therapy,
or as a bridge to transplantation [3, 4] and important considerations for case selection include the extent of disease,
site of the tumor, and history of prior treatments. SBRT
has historically been indicated for patients who are not
eligible for surgical resection or other forms of LRT. However, with emerging evidence demonstrating good local
control and overall survival, there is a trend to increased
use of SBRT for treatment of HCC. In general, patient
with moderately good liver function are candidates for
SBRT [7–9] due to a lower risk of hepatic decompensation compared to patients with more advanced cirrhosis.
More recent studies suggest that patients with poorer liver
function may be treated with SBRT but caution needs to be
exercised given that these patients are extremely sensitive
to radiation associated liver dysfunction [14, 15]. Tumors
that are not amenable to percutaneous ablation, e.g., dome/
subdiaphragmatic lesions, lesions directly adjacent to large
vessels, or lesions with associated tumor in vein (TIV) can
be treated with radiotherapy. The delivery of high doses
of radiotherapy can be limited by tumor location next to
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hollow viscus which are more sensitive to post-radiation
complications. In these cases, SBRT in 3–5 fractions may
not be ideal but these patients can be treated with hypofractionated regimens which is safer for adjacent bowel or
with the use of laparoscopically placed tissue expanders
which displace bowel away from the target lesion. Further,
in cases where liver tolerance cannot be met with photon
radiation, protons may demonstrate superior liver sparing and a much reduced risk of radiation associated liver
toxicity [16–21].
The key to the safe delivery of liver radiation is predicated on the following: evaluation of the patient’s baseline
liver function and extent of disease (recent calculation of
Child Pugh score, recent diagnostic imaging and staging),
a detailed CT and MR simulation scan for clear delineation of the tumor, respiratory control for minimizing tumor
motion, designing a radiation plan that respects known liver
tolerances to mitigate the risk of acute and late toxicity, and
daily image guidance for precise and accurate alignment of
the target [16, 17]. With respect to the first item, as discussed above, baseline liver function directly predicts the
risk of hepatic decompensation post liver radiation as does
the ratio of tumor burden to that of normal/uninvolved liver
parenchyma. Delineation of the gross tumor volume (GTV;
Fig. 1), demonstrable visualized tumor extent, requires at
least a triple-phase contrast CT and/or an MR liver with
contrast. To limit the amount of normal liver parenchyma
in the radiation field, it is imperative to consider motion
management as the liver typically moves 1–3 cm in the superior/inferior direction with respiration. Treating a moving
target with extreme motion requires the treatment of more
normal liver. Strategies such as fiducial markers for gated
treatment and alignment, abdominal compression, or controlled breath-hold techniques should be utilized to limit
liver and tumor motion [17, 22, 23]. The planning target
volume (PTV) is a geometric expansion to account for setup
variability during treatment and is dependent on the radiation machine, the imaging guidance for treatment, and the
immobilization technique used for the patient. For patients
who are able to hold their breath consistently in a controlled
setting, the planning target volume is expanded from the
GTV. In the setting of free breathing treatment where there is
motion of the tumor, an internal target volume (ITV) is constructed to reflect the possible positions of the tumor prior
to expansion to the PTV. (Fig. 1). Creation of the radiation
plan requires knowledge of liver tolerance in patients without liver cirrhosis or dysfunction who may be treated with
SBRT for liver metastases. It is critical to understand the
implications of the mean liver dose as well as consideration
of the low dose splash to the uninvolved liver parenchyma
[8, 9, 24, 25]. Finally, the use of daily cone beam CT or MRlinac is required to ensure safe alignment of the lesion prior
to delivery of an ablative radiation dose.
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Current clinical evidence
There is encouraging evidence from a growing number
of studies evaluating the use of SBRT in the treatment
of HCC, including well-designed phase II trials [26, 27],
to support the safety and feasibility of SBRT for primary
HCC. However, since SBRT is not included in the BCLC
guidelines, the inclusion criteria across these studies were
heterogeneous and SBRT was most commonly evaluated
as a primary treatment modality when patients were not
appropriate candidates for other LRTs. Furthermore, only
few retrospective studies comparing SBRT with other
LRTs are available [28–30].
Even so, data from multiple phase II trials showed
1-year local tumor control rates with SBRT at 82%–96%
and 1-year overall survival rates of 36%–78% [26, 27,
31–33]. Moreover, in a large retrospective cohort of 221
HCC patients, acute toxicities of ≥ grade 3, based on the
Common Terminology Criteria for Adverse Events V3.0
(CTCAE), were observed in only 24 patients (13%), of
which only three complications (1.6%) persisted and the
rest eventually recovered to grade 1–2. Grade 5 toxicity
with acute liver failure occurred was observed in only
two patients [34]. When compared to other LRTs, SBRT
appears to have a favorable toxicity profile with at least
comparable local tumor control and overall survival rates.
A recent retrospective study of 209 patients compared outcomes of TACE and SBRT in patients with 1–2 tumors
while adjusting for imbalances in treatment assignment.
While there was no difference in overall survival between
the two groups, 1-year local control rate was 97% for
SBRT and 47% for TACE (P < 0.001), while acute toxicities of ≥ grade 3 occurred in 13% TACE treatments and
only 8% of SBRT treatments (P = 0.05) [30]. Thus, SBRT
of HCC has a very good safety profile with a small incidence of complications.

Expected imaging findings post SBRT

Fig. 1  Simulation CT scan for liver radiation therapy. a Gross tumor
volume (GTV) is outlined in red, and the yellow clip is a fiducial
marker placed by interventional radiology for localization at the time
of radiation therapy. b Radiation plan. This plan used protons to limit
parenchymal dose. Blue edge is the 50% isodose line. c SBRT plan
using photons. Dark blue denotes GTV, green denotes internal target volume (ITV), and pink denotes PTV. The loculated fluid density
next to the liver is a tissue expander to displace the stomach from the
left hepatic lobe for SBRT

Treatment response assessment after LRT is necessary in
order to evaluate tumor response and to assess for residual
viable tumor. As mentioned, many of these patients are
being downstaged or bridged to liver transplant, and thus
accurate characterization of viable tumor is essential for
identifying tumor burden. SBRT has historically been used
as last-line therapy for HCC treatment, often in patients
who have already undergone other LRTs or are ineligible for surgical resection, and only recently has emerged
as first-line treatment. Therefore, there is a paucity of
explant/resection data in this cohort, resulting in limited
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radiology–pathology correlation in SBRT-treated HCC.
Thus, the significance of the imaging findings after SBRT
are still unknown, although, as mentioned above, outcomes
data suggest overall good efficacy after SBRT, with overall
survival comparable or better than other forms of LRT,
and response rates allowing for bridging and down-staging
for transplant. [30, 35–38]
Imaging features that are used to evaluate for treatment
response after LRT for HCC vary depending on the treatment response classification system being used, and can be
applied to imaging using multiphasic CT or dynamic postcontrast MRI. These imaging criteria include arterial phase
hyperenhancement (APHE), washout (WO) appearance,
enhancement similar to pretreatment, and change in size.
MRI-specific ancillary features of diffusion restriction and
T2-weighted hyperintensity are not strict criteria used for
treatment response assessment based on current treatment
response classification systems. However, a combination of
these imaging characteristics are often used to assess HCC
response to SBRT. In the post-SBRT setting, it is critical
to understand that imaging characteristics evolve over time
and the interval between radiation and time to imaging study
must be considered when assessing SBRT response [39].
Furthermore, radiation-induced changes in the parenchyma
adjacent to the treated tumor add a layer of complexity when
interpreting post-SBRT imaging, as it is often difficult to
distinguish between treated tumor, viable tumor, and the surrounding parenchyma.
After LRT, follow-up imaging can be with either contrastenhanced CT or MRI to evaluate for treatment response.
Timing for follow-up after SBRT varies, but in general,
should be every 3 months after treatment. Imaging less than
3 months after treatment can be confusing because of the
microvascular radiation-induced venoocclusive changes
which occur early post treatment resulting in extensive arterial phase hyperenhancement in the entire treatment zone,
frequently obscuring evaluation of the treated lesion [40,
41].
Most HCCs effectively treated with SBRT exhibit a
slow decrease in size, and thus a measurable change in size
between short interval imaging studies is not always appreciable [42]. One study showed a measurable decrease in size
of 35% at 3 months, 48% at 9 months, and 54% at 12 months
following SBRT. [43] Another report noted that of 67
HCCs treated with SBRT, all either remained unchanged
or decreased in size in the first 12 months post treatment
(34% unchanged and 66% decreased) with none demonstrating an increase in size during this time [44]. Thus, lesions
that are unchanged or decreasing in size post SBRT should
be cautiously interpreted for viability, despite enhancement
characteristics; these lesions should not be considered viable
because they are unchanged in size even if there is persistent
enhancement in the early post-treatment period [45]. On the
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contrary, treated tumor demonstrating increased size post
SBRT is highly suggestive of residual or recurrent, viable
disease [45].
Enhancement patterns of SBRT-treated HCC also evolve
over time. One study noted that 75% of SBRT-treated HCCs
can demonstrate persistent APHE 3–6 months after therapy,
as well as persistent washout. These features slowly resolve
after 6 months, although they can occasionally be seen in
the treated lesion 1 year post SBRT (Figs. 2 and 3) [44, 46].
Eventually, most successfully treated tumors are shown to
convert to non-enhancement [44, 46]. A study by Sanuki
et al. demonstrated that the median time for complete resolution of APHE was 5.9 months (range 1.2–34.2 months) in a
cohort of 38 SBRT-treated HCCs [47]. In this same cohort,
76% of SBRT-treated HCCs had persistent enhancement at
3 months, 33% at 6 months, and 29% at 12 months [47].
Another study by Kimura et al., with 55 lesions, showed persistent APHE in 25.3% of SBRT-treated lesions at 3 months
and 2% residual APHE at 6 months, with no lesions demonstrating increase in size [48]. Price et al. demonstrate similar
findings in a cohort of 26 patients, in which 41% of tumors
had persistent APHE at 3 months, 31% at 6 months, 19%
at 9 months, 8% at 12 months, with tumors demonstrating
progressive decrease in size of the tumor over each time
interval [48].
Another study, which included 35 subjects, found APHE
with portal or delayed phase washout, T2-weighted tissue hyperintensity, and diffusion-weighted hyperintensity
to be key features seen 3 months post SBRT [49]. APHE
was present in all patients at baseline, 45.7% at 3 months,
25.7% at 6 months, and 8.6% at 12 months. T2-weighted
hyperintensity was present in 74.3% at baseline, 36.9% at
3 months, and 5.1% at 12 months. Restricted diffusion was
seen in 62.9% of lesions at baseline, 31.7% at 3 months,
and 6.2% at 12 months [49]. Thus, there is ample emerging
evidence that the presence of persistent APHE on short-term
follow-up is an expected imaging finding post SBRT and
that there is continued temporal evolution of APHE after
SBRT, although some cases may show persistent internal
APHE even at one year post SBRT. Therefore, persistent
APHE does not necessarily indicate the presence of clinical
significant viable tumor.
There is limited research identifying imaging features
which suggest local recurrence after SBRT. However, it has
been reported that an increase in size of a treated lesion or
increasing or new nodular APHE within a lesion should raise
suspicion for SBRT failure and viable tumor [45] (Fig. 4).
The SBRT treatment zone not only includes the targeted tumor, but also a surrounding rim of adjacent hepatic
parenchyma (PTV as described above). As a result, the
surrounding hepatic parenchyma also demonstrates characteristic imaging features which evolve over time. Early
post treatment, there is geographic APHE in off-target
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Fig. 2  Expected post-treatment changes of HCC treated by SBRT
seen on CT within first 4 months. a (i) Axial arterial phase CT from
a multiphasic study shows an enhancing observation in segment VII
measuring 1.1 cm (arrow). (ii) Delayed phase CT shows an enhancing capsule and central washout of contrast within the observation
(arrow). The imaging features are diagnostic of hepatocellular carcinoma. LR 5. b Multiphasic CT was obtained one month post stereotactic body radiation therapy (SBRT). (i) Arterial phase image
shows a decrease in size and degree of enhancement of the segment
VII hepatocellular carcinoma (arrow). (ii) Delayed phase CT shows

enhancement in segment VII similar to background hepatic parenchyma with no washout or capsule. Findings are typical of radiation therapy with no evidence of recurrent tumor. c Multiphasic CT
was obtained four months post SBRT. (i) Arterial phase CT shows
a geographic area of enhancement (arrow) in the radiation field. (ii)
Delayed phase CT shows enhancement in segment VII similar to
background hepatic parenchyma with no washout or capsule. Dilated
bile ducts (arrow) within the treated segment are compatible with
fibrosis. Findings are typical of radiation therapy with no evidence of
recurrent tumor

parenchyma adjacent to the treated HCC, which has been
seen to persist for about 6 months [50]. The histopathological changes have been shown to include hyperemia, small
vessel venous congestion, microhemorrhages, venoocclusion, and a possible giant cell reaction, all of which lead
to architecture changes [44, 51]. In response to decreased
venous inflow, there is increased arterial inflow that manifests on contrast-enhanced imaging as early arterial phase
hyperenhancement (APHE) [51]. Differentiating this from
tumor progression can sometimes be challenging. Lack

of washout or other ancillary features (e.g., T2-weighted
or diffusion-weighted hyperintensity) in this part of the
liver is helpful to differentiate expected post-radiation
perfusional changes from infiltrative tumor [52]. Subsequent cell death, necrosis, and fibrosis contribute to the
change in imaging findings from APHE to portal venous
and delayed phase hyperenhancement, usually 6 months
post SBRT. Additional features seen months after SBRT
include overlying capsular retraction and upstream biliary
ductal dilatation, as a result of radiation-induced fibrosis.
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Fig. 3  Expected post-treatment
changes of HCC treated by
SBRT seen on CT within first
12 months. a (i) Axial arterial
phase CT from a multiphasic
study shows an enhancing
observation in segment VII
(arrow). (ii) Delayed phase
CT shows central washout of
contrast within the observation. Imaging characteristics
are diagnostic of hepatocellular
carcinoma, LR 5 (arrow). b
Multiphasic CT was obtained
6 months post SBRT. (i) The
hepatocellular carcinoma in segment VII (arrow) appears similar to the pretreatment CT. (ii)
The hepatocellular carcinoma
in segment VII again shows
washout on delayed phase
imaging (arrow). The observation is minimally decreased
in size from the pretreatment
study. LR-TR Equivocal c
multiphasic CT was obtained
9 months post SBRT. (i) The
hepatocellular carcinoma in
segment VII is smaller with less
arterial enhancement (arrow)
compared to the pretreatment
images. (ii) The hepatocellular
carcinoma is decreased in size
with persistent washout (arrow).
LR-TR Equivocal Findings are
typical of radiation therapy with
no evidence of recurrent tumor.
d Multiphasic CT was obtained
12 months post SBRT. (i) The
treated segment VII lesion
shows no arterial enhancement.
LR-TR Non-viable (ii) Progressive, geographic enhancement
of the treated liver on delayed
phase CT is compatible with
fibrosis (arrow). There is no
washout. Findings are typical
of radiation therapy with no
evidence of recurrent tumor
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Fig. 4  Recurrent HCC seen on MRI following SBRT treatment. a Dynamic contrast-enhanced MR was performed. (i) Axial
T1-weighted arterial phase image shows an enhancing observation
in segment VII (arrow). (ii) Axial T1-weighted delayed phase image
shows an enhancing capsule and central washout of contrast within
the observation (arrow). The imaging features are diagnostic of hepatocellular carcinoma, LR 5. (iii) The lesion (arrow) is hyperintense on
axial T2-weighted imaging with fat saturation. (iv) The lesion (arrow)
restricts diffusion. b Dynamic contrast-enhanced MR was performed
3 months after SBRT to segment VII lesion. (i) Axial T1-weighted
arterial phase image shows interval decrease in size of the hepatocellular carcinoma in segment VII (arrow). There is mild peripheral and
internal enhancement, a non-specific finding in the setting of recent
SBRT. (ii) Axial T1-weighted delayed phase image shows persistent
enhancement of the lesion with no washout (arrow). LR-TR Equivocal. Geographic enhancement adjacent to the treated lesion is an

expected finding post SBRT. (iii) The lesion remains hyperintense on
axial T2-weighted imaging with fat saturation (arrow). (iv) Restricted
diffusion (arrow) has decreased compared to the pretreatment exam.
C) Dynamic contrast-enhanced MR was performed 9 months after
SBRT to segment VII lesion. (i) Axial T1-weighted arterial phase
image shows interval increase in size of the treated hepatocellular
carcinoma in segment VII (arrow). Peripheral and internal enhancement are similar to increased in intensity. (ii) Axial T1-weighted
delayed phase image shows persistent central enhancement of the
lesion with no washout (arrow). Geographic enhancement adjacent to
the treated lesion is a sequela of SBRT. (iii) The lesion has increased
in size and remains hyperintense on axial T2-weighted imaging with
fat saturation (arrow). (iv) Restricted diffusion has increased (arrow).
Overall, findings are compatible with recurrent hepatocellular carcinoma, LR-TR Viable

Pitfalls in treatment response assessment:
RECIST, mRECIST, LI‑RADS

following LRT, all of which use the imaging finding of
enhancement as a predictor of residual or recurrent disease [1, 53, 54]. EASL uses bidimensional measurements
to evaluate the residual enhancing tumor [55]. mRECIST
utilizes the single largest diameter of the enhancing (during arterial phase) tumor component [2]. LI-RADS TRA
considers a tumor non-viable (LR-TR non-viable) when
there is no appreciable lesion or treatment-specific expected

European Association for the Study of the Liver (EASL),
Modified Response Evaluation Criteria in Solid Tumors
(mRECIST), and Liver Reporting and Data System (LIRADS) treatment response algorithm (TRA) v.2018 are
several of the algorithms used to gauge tumor response

13

Abdominal Radiology

enhancement, viable (LR-TR viable) if there is nodular or
mass-like washout or arterial phase enhancement associated
with the lesion or if enhancement is similar to pretreatment,
and equivocal (LR-TR equivocal) if the pattern of enhancement is atypical for the treatment-specific expected enhancement and does not meet criteria for probably or definitely
viable [54, 56].
Since all of these classification systems use APHE as
an imaging biomarker for detection of viable disease post
treatment, use of these algorithms for treatment response
assessment following SBRT could lead to incorrect characterization of tumor as viable since persistent APHE has
been shown to be an expected imaging feature in successfully treated HCC with SBRT. Such miscategorization could
lead to unnecessary retreatment or negatively impact management, such as disqualifying a patient for liver transplant
or unnecessary start of systemic therapy. However, when
residual APHE is considered a “treatment-specific expected
enhancement pattern” using the LI-RADS TRA criteria, this
system could result in a more accurate characterization of
these lesions as non-viable [45]. Currently, LI-RADS TRA
suggests deeming an SBRT-treated HCC as LR-TR Equivocal if there is persistent APHE early post SBRT, and eventual conversion to LR-TR Non-viable with temporal evolution. Although this may result in an increase in follow-up
imaging studies, as well as the potential of leaving viable
tumors untreated, the risk is generally mitigated by the slow
growth of HCC which typically demonstrates a doubling
time of 85.7–117 days [57, 58]. Thus, caution must be taken
when using the existing treatment response algorithms for
interpretation of HCC treated with SBRT. Importantly, decision-making for management of patients following SBRT
should be made by a multidisciplinary tumor board for best
patient care.

Conclusion
Post-SBRT imaging generally demonstrates predictable temporal evolution of imaging characteristics. The misinterpretation of these findings has the potential to impact clinical
management, including unnecessary additional treatments.
It is important for radiologists to understand the expected
post-SBRT findings, especially the presence of early posttreatment persistent APHE.
Classification systems such as EASL, mRECIST, and
LI-RADS TRA should be cautiously applied when evaluating HCC treated with SBRT. Close collaboration with
the referring clinical team is essential in the assessment of
equivocal findings, taking into consideration clinical findings and tumor markers. Further studies are needed to assess
the clinical utility of current treatment response classification systems related to outcomes data, imaging features such
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as restricted diffusion and T2 signal in treatment response
evaluation, and radiology–pathology data to validate current
imaging characteristics.
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